[
  {
    "ts": null,
    "headline": "BlackRock Capital Appreciation V.I. Fund Q1 2025 Commentary",
    "summary": "BlackRock Capital Appreciation V.I. Fund posted a return of -10.69% (Class I shares) for the first quarter of 2025. Read more here.",
    "url": "https://finnhub.io/api/news?id=1b2fa00a0a5e733ed23500a860dbfee3c7150df1d4547497dc0463c73f91fa0a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747353060,
      "headline": "BlackRock Capital Appreciation V.I. Fund Q1 2025 Commentary",
      "id": 134491616,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1091709538/image_1091709538.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Capital Appreciation V.I. Fund posted a return of -10.69% (Class I shares) for the first quarter of 2025. Read more here.",
      "url": "https://finnhub.io/api/news?id=1b2fa00a0a5e733ed23500a860dbfee3c7150df1d4547497dc0463c73f91fa0a"
    }
  },
  {
    "ts": null,
    "headline": "Does Anavex's Alzheimer's Drug Actually Confer Benefit?",
    "summary": "Does Anavex's Alzheimer's Drug Actually Confer Benefit?",
    "url": "https://finnhub.io/api/news?id=642997139796d1ec22e42b910d04d46a39c8d9d41e0d602b85609a2eb28d3a9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747342160,
      "headline": "Does Anavex's Alzheimer's Drug Actually Confer Benefit?",
      "id": 134486300,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=642997139796d1ec22e42b910d04d46a39c8d9d41e0d602b85609a2eb28d3a9d"
    }
  },
  {
    "ts": null,
    "headline": "INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity",
    "summary": "INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity",
    "url": "https://finnhub.io/api/news?id=b756f83ede5a952ac1cd88a2f2bfbfaeb147a2d8042368572bb7e00b02603f9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747330084,
      "headline": "INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity",
      "id": 134485546,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b756f83ede5a952ac1cd88a2f2bfbfaeb147a2d8042368572bb7e00b02603f9d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d5939b8a60615cde95b636452c65a0f1317ff7f88253b932985a67c733cf479c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747326660,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 134487309,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d5939b8a60615cde95b636452c65a0f1317ff7f88253b932985a67c733cf479c"
    }
  },
  {
    "ts": null,
    "headline": "Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-Editing Therapeutics",
    "summary": "May 15 - Rznomics: * RZNOMICS ENTERS GLOBAL LICENSING AGREEMENT WITH ELI LILLYFORRNA-EDITING THERAPEUTICS * RZNOMICS: UPFRONT PAYMENT WAS NOT DISCLOSED ...",
    "url": "https://finnhub.io/api/news?id=8954149dd0a4cd1c418caf3cc80b8cd1e9932145d614d301f82380cb7ef57b2e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747320915,
      "headline": "Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-Editing Therapeutics",
      "id": 134483279,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "May 15 - Rznomics: * RZNOMICS ENTERS GLOBAL LICENSING AGREEMENT WITH ELI LILLYFORRNA-EDITING THERAPEUTICS * RZNOMICS: UPFRONT PAYMENT WAS NOT DISCLOSED ...",
      "url": "https://finnhub.io/api/news?id=8954149dd0a4cd1c418caf3cc80b8cd1e9932145d614d301f82380cb7ef57b2e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript",
    "summary": "Eli Lilly and Company (NYSE:LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ETCompany ParticipantsLucas Montarce - CFOMike...",
    "url": "https://finnhub.io/api/news?id=b3480c4cd6daa11dfd7057d9105bb3825313e439289ca18b0fab6e770f8713db",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747320718,
      "headline": "Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript",
      "id": 134483346,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (NYSE:LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ETCompany ParticipantsLucas Montarce - CFOMike...",
      "url": "https://finnhub.io/api/news?id=b3480c4cd6daa11dfd7057d9105bb3825313e439289ca18b0fab6e770f8713db"
    }
  },
  {
    "ts": null,
    "headline": "ETFs to Capitalize on the Novo Nordisk-Septerna Deal",
    "summary": "Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.",
    "url": "https://finnhub.io/api/news?id=cdeb9ec50e058187e74940e05043554d5cc5bc7cb742ba08cad899cf77924605",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747317600,
      "headline": "ETFs to Capitalize on the Novo Nordisk-Septerna Deal",
      "id": 134483531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.",
      "url": "https://finnhub.io/api/news?id=cdeb9ec50e058187e74940e05043554d5cc5bc7cb742ba08cad899cf77924605"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Eli Lilly and Company Presents at BofA Securities 2025 Healthcare Conference, May-15-2025 08",
    "summary": "Presenter SpeechUnknown Analyst [Audio Gap] Health U.S. and international roles and we have Mike Czapar, who's Senior Vice President, Investor Relations and back in this role, we've been out of",
    "url": "https://finnhub.io/api/news?id=8e48df6f80650029a06140accebc70b0acfa1b78a09405778acfa758c2ff532e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747313421,
      "headline": "Transcript : Eli Lilly and Company Presents at BofA Securities 2025 Healthcare Conference, May-15-2025 08",
      "id": 134476944,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Presenter SpeechUnknown Analyst [Audio Gap] Health U.S. and international roles and we have Mike Czapar, who's Senior Vice President, Investor Relations and back in this role, we've been out of",
      "url": "https://finnhub.io/api/news?id=8e48df6f80650029a06140accebc70b0acfa1b78a09405778acfa758c2ff532e"
    }
  },
  {
    "ts": null,
    "headline": "Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk",
    "summary": "SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.",
    "url": "https://finnhub.io/api/news?id=406cd1323435f9f2276a93006dfbd60b7d99977f23a742a7fab79a175c0a7d2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747313160,
      "headline": "Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk",
      "id": 134483533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.",
      "url": "https://finnhub.io/api/news?id=406cd1323435f9f2276a93006dfbd60b7d99977f23a742a7fab79a175c0a7d2c"
    }
  },
  {
    "ts": null,
    "headline": "2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed",
    "summary": "The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office.",
    "url": "https://finnhub.io/api/news?id=6e15976d8b5e5df7c39193a3d45bb451ee25b8ce93a45549a40b348d49202043",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747299300,
      "headline": "2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed",
      "id": 134465628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office.",
      "url": "https://finnhub.io/api/news?id=6e15976d8b5e5df7c39193a3d45bb451ee25b8ce93a45549a40b348d49202043"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Large Cap Focus Growth Fund Q1 2025 Commentary",
    "summary": "The fund posted returns ofÂ -10.98%Â (Institutional shares) andÂ -10.98%Â (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=61e5695c9460c0e4a582015204981faa9cf9f49127187b19964ecf18b49e98da",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747293600,
      "headline": "BlackRock Large Cap Focus Growth Fund Q1 2025 Commentary",
      "id": 134465665,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367307651/image_1367307651.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The fund posted returns ofÂ -10.98%Â (Institutional shares) andÂ -10.98%Â (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=61e5695c9460c0e4a582015204981faa9cf9f49127187b19964ecf18b49e98da"
    }
  },
  {
    "ts": null,
    "headline": "3 Market-Beating Stocks with Promising Prospects",
    "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
    "url": "https://finnhub.io/api/news?id=6153320a0901b7adf1d48db87e1cf3c215bd24c906c68cb67ef0aaad2b2ca8f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747283928,
      "headline": "3 Market-Beating Stocks with Promising Prospects",
      "id": 134465640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
      "url": "https://finnhub.io/api/news?id=6153320a0901b7adf1d48db87e1cf3c215bd24c906c68cb67ef0aaad2b2ca8f0"
    }
  }
]